Treatment of MCF7cells with E2 and the PI3K inhibitor Ly294002 significantly enhancedapoptosis compared to those treated with E2 alone, suggesting thatcombining estrogen with a PI3K inhibitor could be a promising strategyfor treating ERα-positive breast cancer. Here, ESR1 is linked to breast carcinoma.